1
|
Loap P, El Ayachy R, Beddok A, Abbassi L, Boilève A, Deau Fischer B, Willems L, Franchi P, Bouscary D, Kirova Y. Evolution of radiotherapy techniques for mediastinal Hodgkin lymphoma: a single-center experience. Mediastinum 2023; 8:10. [PMID: 38322184 PMCID: PMC10839518 DOI: 10.21037/med-23-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 11/20/2023] [Indexed: 02/08/2024]
Affiliation(s)
- Pierre Loap
- Department of Radiation Oncology, Institut Curie, Paris, France
| | | | - Arnaud Beddok
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Louisa Abbassi
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Alice Boilève
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Bénédicte Deau Fischer
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Lise Willems
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Patricia Franchi
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Didier Bouscary
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Youlia Kirova
- Department of Radiation Oncology, Institut Curie, Paris, France
| |
Collapse
|
2
|
Deau Fischer B. [Relapse of Hodgkin lymphoma: second and subsequent line treatments]. Rev Prat 2023; 73:633-636. [PMID: 37458552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 07/20/2023]
Abstract
RELAPSE OF HODGKIN'S LYMPHOMA 2ND AND SUBSEQUENT LINE TREATMENTS. Patients who fail first-line treatment can be cured with salvage chemotherapy followed by intensified therapy and hematopoietic stem cell autotransplantation. This treatment strategy is feasible for patients who are eligible based on their age, with chemosensitive disease and associated comorbidities. There is no standard of care for salvage chemotherapy, but patients who are in complete remission prior to transplantation have the best prognosis. Combinations of salvage therapy, including new molecules, have shown interesting results, but without comparative trials. The use of brentuximab vedotin as a maintenance treatment post autotransplant has been evaluated for patients at high risk of relapse, resulting in a significant improvement in progression-free survival. Allograft is a curative option for postautotransplant relapse; however, immunotherapy with antiPD1 calls into question the role and timing of allograft.
Collapse
|
3
|
Duléry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau Fischer B, Soussain C, Feugier P, Noël N, Choquet S, Bologna S, Joly B, Philippe L, Kohn M, Malak S, Fouquet G, Daguindau E, Taoufik Y, Lacombe K, Cartron G, Thiéblemont C, Besson C. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol 2021; 96:934-944. [PMID: 33909916 PMCID: PMC8212109 DOI: 10.1002/ajh.26209] [Citation(s) in RCA: 88] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 04/23/2021] [Accepted: 04/23/2021] [Indexed: 12/19/2022]
Abstract
Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants and outcomes. Adult patients with lymphoma admitted for Covid-19 to 16 French hospitals in March and April, 2020 were included. Length of in-hospital stay was analyzed as a competitor vs death. The study included 111 patients. The median age was 65 years (range, 19-92). Ninety-four patients (85%) had B-cell non-Hodgkin lymphoma. Within the 12 months prior to hospitalization for Covid-19, 79 patients (71%) were treated for their lymphoma. Among them, 63 (57%) received an anti-CD20 therapy. Fourteen patients (12%) had relapsed/refractory disease. The median LOS was 14 days (range, 1-235). After a median follow-up of 191 days (3-260), the 6-month overall survival was 69%. In multivariable analyses, recent administration of anti-CD20 therapy was associated with prolonged LOS (subdistribution hazard ratio 2.26, 95% confidence interval 1.42-3.6, p < 0.001) and higher risk of death (hazard ratio 2.17, 95% confidence interval 1.04-4.52, p = 0.039). An age ≥ 70 years and relapsed/refractory lymphoma were also associated with prolonged LOS and decreased overall survival. In conclusion, an age ≥ 70 years, a relapsed/refractory lymphoma and recent administration of anti-CD20 therapy are risk factors for prolonged LOS and death for lymphoma patients hospitalized for Covid-19. These findings may contribute to guide the management of lymphoma during the pandemic, support evaluating specific therapeutic approaches, and raise questions on the efficacy and timing of vaccination of this particular population.
Collapse
Affiliation(s)
- Rémy Duléry
- Service d'Hématologie Clinique et de Thérapie Cellulaire Hôpital Saint Antoine, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Inserm UMRs Paris France
| | - Sylvain Lamure
- Département d'Hématologie Clinique, CHU de Montpellier, UMR‐CNRS 5535 Université de Montpellier Montpellier France
| | - Marc Delord
- Clinical Research Center Centre Hospitalier de Versailles Le Chesnay France
| | - Roberta Di Blasi
- Service d'Hématologie‐Oncologie Hôpital Saint Louis, Assistance Publique—Hôpitaux de Paris; Université de Paris – Diderot Paris France
| | | | - Thomas Hueso
- Service d'Hématologie Adulte Institut Gustave Roussy, Université Paris‐Sud, Université Paris‐Saclay Villejuif France
| | - Cédric Rossi
- Service d'Hématologie Clinique CHU de Dijon Bourgogne Dijon France
| | - Bernard Drenou
- Département d'Hématologie Groupe Hospitalier de Mulhouse Sud Alsace Mulhouse France
| | - Bénédicte Deau Fischer
- Service d'Hématologie Clinique Hôpital Cochin, Assistance Publique ‐ Hôpitaux de Paris Paris France
| | - Carole Soussain
- Département d'Oncologie Médicale ‐ Hématologie Institut Curie Saint Cloud France
| | | | - Nicolas Noël
- Service de Médecine Interne – Immunologie Hôpital Bicêtre, Assistance Publique ‐ Hôpitaux de Paris Le Kremlin‐Bicêtre France
| | - Sylvain Choquet
- Service d'Hématologie Clinique Hôpital Pitié‐Salpêtrière, Assistance Publique ‐ Hôpitaux de Paris Paris France
| | - Serge Bologna
- Service d'Hématologie Centre d'Oncologie de Gentilly Nancy France
| | - Bertrand Joly
- Service d'Hématologie Centre Hospitalier Sud Francilien Corbeil‐Essonnes France
| | - Laure Philippe
- Service d'Hématologie Centre Hospitalier d'Annecy Annecy France
| | - Milena Kohn
- Service d'Hématologie Oncologie Centre Hospitalier de Versailles Le Chesnay France
| | - Sandra Malak
- Département d'Oncologie Médicale ‐ Hématologie Institut Curie Saint Cloud France
| | - Guillemette Fouquet
- Service d'Hématologie Clinique Hôpital Cochin, Assistance Publique ‐ Hôpitaux de Paris Paris France
| | | | - Yassine Taoufik
- Service d'Hématologie et Immunologie Biologique Hôpital Bicêtre, Assistance Publique‐Hôpitaux de Paris, INSERM 1186, Institut Gustave Roussy Villejuif France
| | - Karine Lacombe
- Service des Maladies Infectieuses et Tropicales Sorbonne Université, Inserm IPLESP, Hôpital Saint Antoine, Assistance Publique—Hôpitaux de Paris Paris France
| | - Guillaume Cartron
- Département d'Hématologie Clinique, CHU de Montpellier, UMR‐CNRS 5535 Université de Montpellier Montpellier France
| | - Catherine Thiéblemont
- Service d'Hématologie‐Oncologie Hôpital Saint Louis, Assistance Publique—Hôpitaux de Paris; Université de Paris – Diderot Paris France
| | - Caroline Besson
- Service d'Hématologie Oncologie Centre Hospitalier de Versailles Le Chesnay France
- Centre de recherche en Epidémiologie et Santé des Populations (CESP), INSERM U1018 Université Paris‐Saclay, UVSQ, Inserm, Équipe Villejuif France
| |
Collapse
|
4
|
Le Ray E, Belin L, Plancher C, Anract P, Babinet A, Dumaine V, Tamburini J, Deau Fischer B, Willems L, Magro L, Facon T, Leleu X, Bouscary D, Kirova YM. Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy. Leuk Lymphoma 2017; 59:1756-1758. [PMID: 29087212 DOI: 10.1080/10428194.2017.1393667] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Emmanuelle Le Ray
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France
| | - Lisa Belin
- c Department of Biostatistics , Institut Curie , Paris , France
| | - Corine Plancher
- c Department of Biostatistics , Institut Curie , Paris , France
| | - Philippe Anract
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,d Service de chirurgie orthopédique , Hôpital Cochin, AP-HP , Paris , France
| | - Antoine Babinet
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,d Service de chirurgie orthopédique , Hôpital Cochin, AP-HP , Paris , France
| | - Valérie Dumaine
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,d Service de chirurgie orthopédique , Hôpital Cochin, AP-HP , Paris , France
| | - Jérôme Tamburini
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,e Institut Cochin, Département Développement Reproduction Cancer , CNRS UMR8104, INSERM U1016 , Paris , France
| | - Bénédicte Deau Fischer
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France
| | - Lise Willems
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France
| | | | - Thierry Facon
- f Service d'Hématologie , CHRU Lille , Lille , France
| | - Xavier Leleu
- g Service d'hématologie , CHU de Poitiers , Poitiers , France
| | - Didier Bouscary
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,e Institut Cochin, Département Développement Reproduction Cancer , CNRS UMR8104, INSERM U1016 , Paris , France
| | - Youlia M Kirova
- h Department of Radiation Therapy , Institut Curie , Paris , France
| |
Collapse
|
5
|
Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, Davi F, Settegrana C, Berger F, Alric L, Cacoub P, Terrier B, Suarez F, Sibon D, Dupuis J, Feray C, Tilly H, Pol S, Deau Fischer B, Roulland S, Thieblemont C, Leblond V, Carrat F, Hermine O, Besson C. In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. PLoS One 2016; 11:e0156384. [PMID: 27257992 PMCID: PMC4892517 DOI: 10.1371/journal.pone.0156384] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 05/15/2016] [Indexed: 12/15/2022] Open
Abstract
Hepatitis C Virus (HCV) infection is associated with the B-cell non-Hodgkin lymphomas (NHL), preferentially marginal zone lymphomas (MZL) and diffuse large B-cell lymphomas (DLBCL). While chronic antigenic stimulation is a main determinant of lymphomagenesis in marginal zone lymphomas (MZL), a putative role of HCV infection of B-cells is supported by in vitro studies. We performed a pathological study within the "ANRS HC-13 LymphoC" observational study focusing on in situ expression of the oncogenic HCV non structural 3 (NS3) protein. Lympho-C study enrolled 116 HCV-positive patients with B-NHL of which 86 histological samples were collected for centralized review. Main histological subtypes were DLBCL (36%) and MZL (34%). Almost half of DLBCL (12/26) were transformed from underlying small B-cell lymphomas. NS3 immunostaining was found positive in 17 of 37 tested samples (46%). There was a striking association between NS3 detection and presence of high grade lymphoma features: 12 out of 14 DLBCL were NS3+ compared to only 4 out of 14 MZL (p = 0.006). Moreover, 2 among the 4 NS3+ MZL were enriched in large cells. Remarkably, this study supports a new mechanism of transformation with a direct oncogenic role of HCV proteins in the occurrence of high-grade B lymphomas.
Collapse
Affiliation(s)
- Danielle Canioni
- Department of Pathology, Paris Descartes University, AP-HP, Sorbonne Paris Cité, Hôpital Necker, Paris, France
- * E-mail: (CB); (DC); (OH)
| | - Jean-Marie Michot
- Department of Hematology and Drug Development, Gustave Roussy Institute, Villejuif, F-94805, France
| | - Pascaline Rabiega
- Institut Pierre Louis d’Epidémiologie et de Santé Publique INSERM UMR S1136, Paris 6 Pierre et Marie Curie University, Paris, France
| | - Thierry J. Molina
- Department of Pathology, Paris Descartes University, AP-HP, Sorbonne Paris Cité, Hôpital Necker, Paris, France
| | - Frédéric Charlotte
- Department of Pathology, HôpitalPitié-Salpétrière, Paris 6 Pierre et Marie Curie University, Paris, France
| | - Thierry Lazure
- Department of Pathology, Paris 11 Sud University, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Frédéric Davi
- Department of Biological Hematology, Paris 6 Pierre et Marie Curie University, AP-HP, Hôpital Pitié-Salpétrière, Paris, France
| | - Catherine Settegrana
- Department of Biological Hematology, Paris 6 Pierre et Marie Curie University, AP-HP, Hôpital Pitié-Salpétrière, Paris, France
| | - Françoise Berger
- Department of Pathology, Hopital Lyon Sud, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France
| | - Laurent Alric
- Department of Internal Medicine and Digestive Diseases, Toulouse 3 University, UMR 152 IRD, Hôpital Purpan, Toulouse, France
| | - Patrice Cacoub
- Department of Internal Medicine, APHP, Hôpital Pitié-Salpétrière, Paris 6 Pierre et Marie Curie University, UMR 7211, INSERM, UMR S 959, CNRS, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, APHP, Hôpital Pitié-Salpétrière, Paris 6 Pierre et Marie Curie University, UMR 7211, INSERM, UMR S 959, CNRS, Paris, France
| | - Felipe Suarez
- Department of Adult Hematology, Paris 5 Descartes University, AP-HP, Hôpital Necker, Paris, France
- Imagine Institute, University Sorbonne Paris Cité, INSERM U 1163, CNRS ERL 8254, Paris, France
| | - David Sibon
- Department of Adult Hematology, Paris 5 Descartes University, AP-HP, Hôpital Necker, Paris, France
- Imagine Institute, University Sorbonne Paris Cité, INSERM U 1163, CNRS ERL 8254, Paris, France
| | - Jehan Dupuis
- Department of Lymphoid Malignancies and Clinical Hematology, Paris 12 Est Créteil University, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - Cyrille Feray
- Department of Hepatology, Nantes University, Hôpital de Nantes, Nantes, France
| | - Hervé Tilly
- Department of Hematology, Rouen University, Centre Henri Becquerel, Rouen, France
| | - Stanislas Pol
- Department of Hepatology, Paris 5 Descartes University, INSERM U-1016, AP-HP, Hôpital Cochin, Paris, France
| | - Bénédicte Deau Fischer
- Department of Hematology, Paris Descartes University, AP-HP, Hôpital Cochin, Paris, France
| | - Sandrine Roulland
- Centre d'Immunologie de Marseille Luminy, Aix-Marseille Université INSERM U1104 CNRS UMR7280, Marseille, France
| | - Catherine Thieblemont
- Department of Hemato-oncology, University Paris Sorbonne P7, INSERM U728, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Véronique Leblond
- Department of Clinical Hematology, Paris 6 Pierre et Marie Curie, Paris, France
| | - Fabrice Carrat
- Institut Pierre Louis d’Epidémiologie et de Santé Publique INSERM UMR S1136, Paris 6 Pierre et Marie Curie University, Paris, France
| | - Olivier Hermine
- Department of Adult Hematology, Paris 5 Descartes University, AP-HP, Hôpital Necker, Paris, France
- Imagine Institute, University Sorbonne Paris Cité, INSERM U 1163, CNRS ERL 8254, Paris, France
- * E-mail: (CB); (DC); (OH)
| | - Caroline Besson
- Department of Internal Medicine & Clinical Immunology Biological Immunology and Hematology, Paris 11 Sud University, AP-HP, Hôpital Bicêtre, INSERM U 1184, Le Kremlin-Bicêtre, France
- * E-mail: (CB); (DC); (OH)
| | | |
Collapse
|
6
|
Brandt MR, Furness MS, Rice KC, Fischer BD, Negus SS. Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. J Pharmacol Exp Ther 2001; 299:629-37. [PMID: 11602675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
Tolerance and dependence after acute or chronic administration of the selective delta-opioid agonist SNC80 were assessed in rhesus monkeys (Macaca mulatta) responding under a schedule of food presentation. SNC80 dose dependently decreased response rates. These effects waned after 5 h. When administered as an acute 24-h pretreatment, SNC80 (1.0-10.0 mg/kg) produced tolerance as evidenced by dose-dependent rightward shifts in the SNC80 dose-effect curve. Pretreatments of 3.2 or 10.0 mg/kg SNC80 increased the SNC80 ED50 by 4- or 25-fold, respectively. Tolerance to acute SNC80 was also time-dependent as evidenced by increased ED50 values when administered as a 5-h (14-fold), 24-h (25-fold), or 3-day (11-fold) pretreatment. The SNC80 dose-effect curve was similar to control after a 7-day pretreatment. The selective delta-antagonist naltrindole (1.0 mg/kg) partially blocked tolerance to acute SNC80. Chronic SNC80 (1.0-10.0 mg/kg/day) also produced dose-dependent rightward shifts in the SNC80 dose-effect curve. Chronic SNC80 was more effective than acute SNC80 in producing tolerance. Moreover, tolerance to chronic SNC80 waned more slowly than to acute SNC80. Acute or chronic SNC80 (10.0 mg/kg/day) also produced cross-tolerance to the rate-decreasing effects of other delta-agonists (SNC162 and SNC243A) but not to mu- (morphine) or kappa (U-50,488)-agonists. Changes in response rates or behavioral signs of withdrawal were not observed after the administration of opioid antagonists (i.e., naltrindole or naltrexone) in monkeys treated with SNC80. These data suggest that a pharmacologically selective tolerance develops to delta-agonists after both acute and chronic administration of SNC80 with little or no dependence.
Collapse
MESH Headings
- Animals
- Behavior, Animal/drug effects
- Benzamides/pharmacology
- Conditioning, Operant/drug effects
- Dose-Response Relationship, Drug
- Drug Tolerance
- Female
- Food
- Macaca mulatta
- Male
- Narcotic Antagonists/pharmacology
- Piperazines/pharmacology
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, mu/agonists
- Reinforcement Schedule
- Reinforcement, Psychology
- Substance-Related Disorders
Collapse
Affiliation(s)
- M R Brandt
- Alcohol and Drug Abuse Research Center, Harvard Medical School-McLean Hospital, Belmont, Massachusetts 02178-9106, USA.
| | | | | | | | | |
Collapse
|
7
|
Negus SS, Pope HG, Kanayama G, Wines JD, Fischer BD. Lack of evidence for opioid tolerance or dependence in rhesus monkeys following high-dose anabolic-androgenic steroid administration. Psychoneuroendocrinology 2001; 26:789-96. [PMID: 11585679 DOI: 10.1016/s0306-4530(01)00028-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Prolonged use of high-dose anabolic-androgenic steroids (AAS) may induce a dependence syndrome, and emerging evidence suggests that AAS effects on endogenous opioid systems may contribute to AAS abuse. The present study tested the hypothesis that high dose AAS treatment enhances endogenous opioid activity in rhesus monkeys as revealed by 1) tolerance to the antinociceptive effects of the mu opioid agonist morphine and 2) physical dependence as indicated by evidence of opioid withdrawal following administration of the opioid antagonist naloxone. Three rhesus monkeys were treated for 14 days with 3.2 mg/kg/day testosterone propionate, and the effects of morphine (0.32-10 mg/kg) and naloxone (0.01-0.32 mg/kg) were examined both before and during treatment. Morphine antinociception was evaluated using a warm-water tail-withdrawal procedure, and naloxone-precipitated withdrawal was evaluated using checked behavioral signs and measures of ventilatory rate. Chronic testosterone administration for 14 days produced a 100-fold increase in mean plasma testosterone levels. However, testosterone treatment did not significantly alter the antinociceptive effects of morphine, and naloxone did not precipitate signs of opioid withdrawal either before or during testosterone treatment. These data do not support the hypothesis that high-dose AAS treatment enhances endogenous opioid activity in rhesus monkeys in a way that produces opioid tolerance or dependence.
Collapse
Affiliation(s)
- S S Negus
- Alcohol and Drug Abuse Research Center: Behavioral Science Laboratory, McLean Hospital-Harvard Medical School, 115 Mill St., Belmont, MA 02478, USA.
| | | | | | | | | |
Collapse
|